Pacer Advisors Inc. Boosts Holdings in Humana Inc. (NYSE:HUM)

Pacer Advisors Inc. boosted its position in Humana Inc. (NYSE:HUM) by 58.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,579 shares of the insurance provider’s stock after acquiring an additional 5,750 shares during the quarter. Pacer Advisors Inc.’s holdings in Humana were worth $3,953,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. KBC Group NV raised its position in Humana by 26.0% in the 4th quarter. KBC Group NV now owns 48,685 shares of the insurance provider’s stock valued at $12,352,000 after purchasing an additional 10,039 shares during the last quarter. Blue Trust Inc. boosted its position in shares of Humana by 15.3% during the 4th quarter. Blue Trust Inc. now owns 1,692 shares of the insurance provider’s stock worth $429,000 after purchasing an additional 224 shares in the last quarter. Kingswood Wealth Advisors LLC boosted its holdings in Humana by 23.0% during the fourth quarter. Kingswood Wealth Advisors LLC now owns 9,379 shares of the insurance provider’s stock worth $2,380,000 after buying an additional 1,751 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in shares of Humana by 8.5% in the 4th quarter. Exchange Traded Concepts LLC now owns 1,191 shares of the insurance provider’s stock worth $302,000 after acquiring an additional 93 shares during the period. Finally, Secure Asset Management LLC acquired a new stake in Humana in the fourth quarter valued at $244,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HUM has been the subject of a number of analyst reports. Barclays boosted their price target on Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 22nd. Truist Financial boosted their price objective on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Stephens restated an “equal weight” rating and set a $250.00 price target on shares of Humana in a research note on Wednesday, October 9th. Royal Bank of Canada reduced their price objective on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, Sanford C. Bernstein upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price target on the stock in a report on Tuesday, October 8th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $297.68.

Humana Price Performance

HUM stock opened at $296.88 on Friday. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $35.75 billion, a PE ratio of 26.30, a P/E/G ratio of 2.15 and a beta of 0.55. The stock’s 50 day moving average is $275.44 and its two-hundred day moving average is $303.07.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Analysts predict that Humana Inc. will post 16.11 earnings per share for the current fiscal year.

Insider Transactions at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.